Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Exclusion Criteria

• •Required systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic;
• •High risk of bleeding;
• •Severe renal impairment (estimated creatinine clearance \<30 mL/min);
• •ECOG (Eastern Cooperative Oncology Group) performance status 3 \& 4;
• •Major surgery within 4 weeks before randomization;
• •Known hypersensitivity to unfractionated heparin \[UFH\] or low molecular weight heparin \[LMWH\].
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial